Screener
Novanta NOVT Medical Solutions — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novanta in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Novanta’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335404
| Depreciation and Amortization Expenses | Three Months Ended / July 3, 2026 | Three Months Ended / June 27, 2025 | Six Months Ended / July 3, 2026 | Six Months Ended / June 27, 2025 |
|---|---|---|---|---|
| Automation Enabling Technologies | $5,681 | $5,445 | $9,880 | $10,921 |
| Medical Solutions | 8,608 | 9,745 | 18,185 | 17,424 |
| Unallocated | 359 | 391 | 743 | 799 |
| Total | $14,648 | $15,581 | $28,808 | $29,144 |
Item 1. Financial Statements
FAQ
- What is Novanta's medical solutions — D&A?
- Novanta (NOVT) reported medical solutions — D&A of $8.61M in Q2 2026.
- How has Novanta's medical solutions — D&A changed year-over-year?
- Novanta's medical solutions — D&A decreased by 11.7% year-over-year, from $9.75M to $8.61M.
- What is the long-term trend for Novanta's medical solutions — D&A?
- Over 4 years (2021 to 2025), Novanta's medical solutions — D&A has grown at a 16.2% compound annual growth rate (CAGR), from $20.81M to $37.96M.
- What does medical solutions — D&A mean?
- This represents the total non-cash expense allocated to the wear and tear, obsolescence, or exhaustion of tangible and intangible assets over their useful lives. It is a critical component for calculating EBITDA and understanding the capital intensity of the segment's operations. Higher levels often indicate a larger base of fixed assets or significant recent investments in infrastructure.
Ask your AI about Novanta's medical solutions — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude